Glp-1および抗糖尿病薬sgLT2製剤の心筋梗塞および超高感度炎症サーベイランスへの効果(GALACTUS試験) (GALACTUS)
GLP-1および抗糖尿病薬SGLT2阻害薬を用いた心筋梗塞と超高感度炎症サーベイランスに関するオープンラベルパイロット研究
The primary risk factor for coronary artery disease is atherosclerosis, with inflammation playing a crucial role in the development and progression of this condition. It has now been proven that inflammation is key in the development of complications after an acute myocardial infarction. These complications can be immediate and mechanical, such as ventricular wall rupture and ventricular arrhythmia, or long-term, presenting as major cardiovascular events like heart failure.
During acute myocardial infarction (AMI), circulating high-sensitivity CRP levels increase approximately 6 hours after the onset of ischemia. CRP levels measured between 24 and 72 hours after symptom onset are a significant prognostic marker for one-year outcomes. Higher high-sensitivity CRP levels at the time of AMI are linked to more severe coronary atherosclerotic lesions seen on angiography and lower LVEF one month after the event. A serum high-sensitivity CRP concentration greater than 10 mg/L after an AMI indicates inflammation, reflecting myocardial necrosis, plaque rupture, and acute thrombosis. In patients with AMI, persistent or increasing CRP levels are strongly associated with a higher risk of all-cause and non-cardiovascular death, especially when inflammation (CRP > 2.0 mg/L) continues for a year.
Aside from reperfusion therapy, very few pharmacological approaches have been used to reduce inflammation after AMI. One such approach was the use of colchicine in the COVERT-MI randomized, double-blind, multicenter trial. This trial compared five days of oral colchicine with a placebo and found no difference in infarct size between the groups at five days or three months, as measured by cardiac magnetic resonance imaging.
SGLT-2 inhibitors are drugs that have revolutionized the management of cardiovascular diseases, offering proven benefits for patients with heart failure and notable nephroprotective effects. However, their use after acute myocardial infarction has not yet been sufficiently established, as the only two published clinical trials so far failed to meet their primary goal of reducing hospitalizations for heart failure. Additionally, evidence of their use in post-AMI inflammation exists only in experimental studies. In experimental studies, SGLT2 global-knockout (KO) mice were used to demonstrate that dapagliflozin significantly influences cardiac fibrosis and inflammation, and markedly alters the gene expression profiles of macrophages and fibroblasts. Moreover, dapagliflozin directly inhibited macrophage-mediated inflammation, thereby suppressing cardiac fibroblast activation.
Similarly, only experimental studies have shown that semaglutide decreases elevated levels of TNF-α, IL-6, ROS, and MDA in the serum and cardiac tissues of obese mice. By lowering the expression of Cxcl2, S100a8, and S100a9 in neutrophils, semaglutide may help reduce cardiac inflammation and oxidative stress.
Therefore, the objective of this study is to compare the effects of dapagliflozin and semaglutide on inflammatory markers (hs-CRP and IL-6) in patients with acute ST-segment elevation myocardial infarction.
調査の概要
詳細な説明
This is a small open-label pilot clinical trial to assess the effectiveness of dapagliflozin and semaglutide on inflammatory markers (IL-6 and hs-CRP) in patients with STEMI over 24 weeks. It will include patients over 18 years old with STEMI, with or without a diagnosis of type 2 diabetes, clinical obesity, and an initial serum hs-CRP level greater than 2.0 mg/L.
Inflammation markers will be measured upon patient admission after percutaneous coronary intervention and again after 24 weeks of treatment with the drugs. Patients will be discharged in accordance with STEMI treatment guidelines, and their medication adherence and tolerability will be monitored.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Guanajuato
-
León、Guanajuato、メキシコ、37320
- Hospital de Especialidades No.1, Centro Médico Nacional del Bajío
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Criteria for the fourth definition of acute myocardial infarction with ST-segment elevation.
- Diagnosed with type 2 diabetes.
- Initial serum high-sensitivity CRP value > 2.0 mg/L.
- Clinically obese.
- LVEF >50%.
Exclusion Criteria:
- Patients who have recently received immunosuppressive therapy
- Patients with a history of ischemic heart disease
- Known allergy to any of the medications used
- Use of any of the study drugs more than 6 months prior to randomization
- Patients experiencing diabetic ketoacidosis
- Patients with hemodynamic instability (mean arterial pressure <60 mmHg while on vasopressors)
- Pregnant women
- Patients with a history or current diagnosis of cancer
- Patients with documented active infections, such as pneumonia or urinary tract infections
- Patients with pancreatitis
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Dapagliflozin
Dapagliflozin 10 mg daily for 24 weeks |
10 mg dapagliflozin daily for 24 weeks |
|
アクティブコンパレータ:Semaglutide
Semaglutide 3 mg, gradually increasing to 14 mg every 24 hours over 24 weeks. |
Semaglutide 3 mg, gradually increasing to 14 mg every 24 hours over 24 weeks. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Inflammatory markers (high-sensitivity PCR)
時間枠:24 weeks.
|
Patients with hsCRP > 2 mg/L will be included, and a control will be taken to assess the change after 24 weeks of treatment. |
24 weeks.
|
|
Inflammatory markers (interleukin 6)
時間枠:24 weeks
|
Patients with IL-6 > 2 ng/L will be included, and a control will be taken to assess the change after 24 weeks of treatment. |
24 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Epicardial fat
時間枠:24 weeks
|
Epicardial fat will be assessed using non-invasive coronary tomography during hospitalization for STEMI and again after 24 weeks of treatment. |
24 weeks
|
|
LDL cholesterol
時間枠:24 weeks
|
The impact of both interventions on LDL levels will be assessed after 24 weeks of treatment. |
24 weeks
|
|
Change in glucose and HbA1c
時間枠:24 weeks
|
The effect of both interventions on fasting glucose and HbA1c levels will be assessed after 24 weeks of treatment. |
24 weeks
|
協力者と研究者
捜査官
- 主任研究者:Rodolfo Guardado-Mendoza, Ph.D.、Universidad de Guanajuato
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。